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Tumor necrosis factor-a augments the pro-inflammatory
interaction between PMN and GBM via a CD18
dependent mechanism
KIERON L. DoNov, GERALD A. COLES, and JOHN D. WILLIAMS
Institute of Nephrology, University of Wales College of Medicine, Royal Infirmaiy, Cardiff Wales, United Kingdom
Tumor necrosis factor-a augments the pro-inflammatory interaction
between PMN and GBM via a CD18 dependent mechanism. Acute
glomerulonephritis is frequently associated with intraglomerular neutro-
phil (PMN) accumulation and the intensity of the inflammatory reaction is
correlated with elevated concentrations of pro-inflammatory cytokines
such as tumor necrosis factor-a (TNFa). PMN are thought to damage
glomeruli due to a combination of reactive oxygen species and proteolytic
enzymes. Using an in Vitro model of anti-GBM nephritis the effects of
TNFa on GBM damage by PMN were evaluated. The interaction of GBM
and PMN resulted in a low grade respiratory burst that was significantly
augmented by the addition of TNFa. Luminol dependent chemilumines-
cence (LCL) was increased from 2.4 x 106 to 48.1 X 10° (P < 0.05). The
GBM induced LCL could be >85% inhibited by blocking with monoclonal
antibodies (mAbs) to the common /3 chain of the PMN /32 integrin family
(CD18), but was unaffected by mAbs to CD11a or CD11b subunits.
Degradation of GBM, however, was not influenced by either TNFa
priming of PMN or anti-f32 integrin mAbs. When PMN were incubated
with GBM-anti-GBM IgG complex they underwent an increase in LCL
from 2.4 X 106 to 31.1 )< 10°. They also degraded more GBM than
controls (10.1% vs. 1.8%). These aspects of PMN activation were Fc
receptor mediated, dependent upon anti-GBM IgG being bound to GBM
and inhibited by mAb to the PMN Fc receptor. These studies show that
TNFa can modulate the inflammatory response of PMN in contact with
GBM in a CD18 dependent manner. In contrast, Fc receptor mediated
events are uninfluenced by TNFa.
Certain forms of both human and experimental glomerulone-
phritis (GN) are characterized by an intraglomerular accumula-
tion of PMN which is coincident with the onset of the early phase
of proteinuria [1—31. The filtration barrier of the glomerulus
comprises a combination of the glomerular basement membrane
(GBM) and the epithelial cell slit pores [41, and PMN induced
proteinuria has generally been attributed to damage of this
barrier. Focal disruption of basement membranes by diapedesing
PMN has been seen in animal models of inflammation and
basement membrane fragments have been detected in the urine of
patients with acute GN [5]. While the precise mechanisms respon-
sible for glomerular damage are still unclear, they are likely to
involve PMN derived proteinases, which can degrade basement
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membranes and injure cells [2, 6, 7], and reactive oxygen species
(ROS) which are both cytotoxic and pro-inflammatory [8, 9].
There is increasing evidence that cytokines play an important role
in the inflammatory response of GN, both in an amplifying and
ameliorating manner. The pro-inflammatory cytokine, tumor ne-
crosis factor-a, has been shown to exacerbate renal injury in an
animal model of nephrotoxic nephritis and to cause intraglomeru-
lar PMN accumulation with concomitant proteinuria [10]. It has
also been noted to worsen renal dysfunction in humans during
extra renal inflammatory/infectious conditions [11]. Recent stud-
ies have demonstrated that TNFa may directly influence the
interaction between PMN and several isolated structural proteins
such a laminin and fibronectin via /32 integrin adhesion receptors
which may lead to PMN activation [121.
In the present study we have analyzed the effect of TNFa on the
interactions between intact human PMN and homologous glomer-
ular basement membrane (GBM) in vitro. Monoclonal antibody
blocking experiments suggest that TNFa specifically augments
PMN respiratory burst activity induced by GBM via a CD18
dependent pathway. These findings suggest a possible mechanism
by which TNFa, PMN and GBM may interact to exacerbate the
damage to the glomerular filtration barrier during anti-GBM GN.
Methods
PMN preparation
Human PMN were prepared using a modified Ficoll-Paque
(Pharmacia LKB Biotechnology, Uppsala, Sweden) density gra-
dient centrifugation technique [131. Preparations were routinely
>95% PMN by microscopy and >95% viable as judged by the
exclusion of trypan blue dye. In the present study PMN from six
different donors were studied.
Glomerular basement membrane
Human glomerular basement membrane (GBM) was prepared
in a cold room by a sieving method based on that of Westberg and
Michael [14]. GBM was lyophilized and the individual prepara-
tions were pooled. Preparations were judged to be both endotoxin
free by the limulus amoebocyte lysate assay, and DNA free as
assessed by the diphenylamine colorimetric assay.
698
Donovan et al: Role of CDI8 in PMN interaction with GBM 699
Anti-GBM IgG
Anti-GBM IgG was prepared by sepharose protein-A (Pharma-
cia LKB Ltd, Milton Keynes, UK) affinity chromatography of
plasma obtained during the first and second plasmapharesis of
patients with biopsy and serologically proven anti-GBM disease.
Normal control human IgG was prepared in an identical manner
from pooled normal human serum. The purity of the IgG was
established by SDS-PAGE with silver staining. Western blot
analysis of collagenase digests of GBM incubated with the anti-
GBM IgG showed reactivity with the NC1 monomers and dimers,
as previously described [15]. GBM with bound anti-GBM IgG was
prepared by incubating the antibody with GBM (1 mg IgG per mg
GBM) overnight at 37°C followed by extensive washing (X 4).
Binding of IgG to GBM was assessed using iodinated IgG and was
in the order of 1 tg of IgG/mg GBM.
Control GBM pre-incubated with non-immune IgG, when
added to PMN, produced identical results to GBM pre-incubated
in buffer alone. The latter was therefore used as control GBM in
all experiments.
Tumor necrosis factor-a
Recombinant human tumor necrosis factor-a (TNFa) was a gift
of Dr. Adolf (Boehringer Mannheim, Vienna, Austria). TNFa
was stored at a concentration of I JiM at —70°C. Immediately
before use it was thawed and diluted to a concentration 10 nM.
One hundred jil of diluted TNFa was added to 800 jil of buffer
containing 5 X 106 PMN (Final concentration of I nM). PMN
were primed for 30 minutes at room temperature prior to being
added to the GBM stimulus (100 l, 0.5 mg). A final concentra-
tion of 1 n was chosen based on previous studies since this had
been found to prime PMN, augmenting subsequent interactions
with a number of stimuli, including GBM [16].
Monoclonal antibodies
Monoclonal antibodies (mAbs) to integrin receptor subunits
were as follows. IB-4 mouse mAb to CD 18 (anti-CDI8-i) was a
gift from Dr. S. Wright (NY, USA). Rat mAb to CD 18
(YFC-118.3, anti-CD18-2) was obtained from Serotec (Indianap-
olis, IN, USA) and F(ab')2 fragments prepared by pepsin diges-
tion. Two different anti-CD11b antibodies were obtained from
Serotec (mAb 44, anti-CD11b-1) and Rao (Ortho Diagnostics,
Raritan, NJ, USA) mAb 0KM 10, anti-CDIIb-2). An mAb to
CDI Ia (TS1122) was a gift of Dr. R. Rothlein. Mouse anti-PMN
FcRIII (CD 16) mAb was obtained from Serotec. All antibodies
were used at final concentrations of 5 and 10 Jig/ml diluted in
Krebs-Ringer phosphate glucose buffer pH 7.3 (KRPG: Na2HPO4
10 mM, NaH,P04.2H20 3 mvi, NaCI 120 mi, KCI 4.8 mM, CaCI2
0.54 mrvi, MgSO4 7H0 1.2 mrvi, 13 D-glucose 11 mM).
In vitro model
PMN (50 X 106/mI) were pre-treated for 30 minutes with either
KRPG alone or with KRPG containing TNFa (1 nM), at room
temperature for 30 minutes. Each of these aliquots of PMN was
then incubated for a further 30 minutes at room temperature with
KRPG alone or with KRPG containing one of the monoclonal
antibodies at an optimal concentration (5 to 10 Jig/mi). After
pre-treatment, PMN (5 X 106/ml) were incubated with GBM (0.5
mg) in suspension (total volume I ml) in a non-agitated system in
which both GBM and PMN settled onto the bottom of the
reaction tube. This model has previously been shown to allow
PMN to interact with the GBM, after which they undergo
activation with the generation of reactive oxygen species and the
release of proteolytic enzymes [13. It is difficult to gauge how
closely this model reflects the in vivo situation. Animal models
suggest that up to 5 PMN are seen within each glomerular section
during the height of the PMN dependent phase of experimental
anti-GBM nephritis. Since there are approximately 1.5 million
glomeruli per kidney and the estimated GBM content is -—50 mg
per kidney, this would mean that at any one point in time in vivo
—150,000 PMN are in contact with each mg of GBM. Clearly the
present study contains proportionately more PMN (10 million per
mg of GBM) than would be seen if such a static or 'snapshot'
calculation were used.
However, in vivo new PMN are constantly perfusing glomeruli
so that over a given time period the number of PMN in contact
with GBM might be considerably greater than that estimated in
the single time point of histological analysis. Therefore if the
normal renal plasma flow is 600 mI/mm and the normal PMN
content of plasma is 4 >< 106 per ml, then the total number of
PMN theoretically in each glomerulus can be estimated as 600 X
4 X 106/3 X 10' = 800per minute. If the dynamic calculations are
employed there are potentially 3 million PMN per minute in
contact with each mg of GBM during each minute. Thus over the
incubation periods used in the in vitro model the number of PMN
used would tend to approximate the dynamic in vivo situation. We
therefore feel that our in vitro model reasonably attempts to
reflect what might be occurring in vivo.
GBM degradation
The breakdown of GBM was measured by the release of
hydroxyproline into the incubation supernatant by a modified
chioramine T method [17]. Hydroxyproline was detected by the
development of a pink color measured at 560 n on a Cecil CE
292 spectrophotometer (Cecil Instruments, Cambridge, UK). The
quantity of hydroxyproline released was determined from a
standard curve using pure L-hydroxyproline over the range of 0 to
5 Jig/mi. Results are expressed as the mean % total hydroxypro-
line release (divide the total supernatant hydroxyproline by the
sum of the pellet and supernate values for each incubation).
PMN respiratoly burst activity
PMN respiratory burst activity was determined by luminol (50
l.LM) enhanced chemiluminescence (LCL) over 120 minutes at
37°C using a Berthold LB 950 spectrophotometer (Berthold
Instruments, St Albans, UK) [18, 19]. Luminol reacts with the
ROS generated by PMN to emit light which is detected by the
spectrophotometer. In this way ROS generation can be followed
over a time course, with the integrated total energy released being
a measure of ROS formation. This technique allowed the mea-
surement of ROS generation throughout the incubation period
without disturbing the incubates. Results are expressed as mean
integrated counts over a 120 minute incubation (± SEM) minus
values for cells incubated in the absence of GBM.
PMN viability
PMN viability during and after incubations was determined by
the release of lactate dehydrogenase (LDH) [13] by a microtiter
assay using a plate reader (MR5000/340, Dynatech Laboratories
mc, Billingshurst, UK) [13]. LDH release was calculated as a
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percentage of the total LDH content released by fully sonicated
PMN prepared from the same donor.
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Statistical methods
Each experiment was performed in triplicate, and the results
meaned, using PMN from up to six separate donors. The result
represents the mean value (± sEM) from all donors and N = the
number of donors. Data were compared using the Student's t-test,
and P < 0.05 was considered significant.
Results
Role of f32 integrins in GBM-PMN interaction
The interaction of human PMN with native GBM resulted in a
low grade respiratory burst which was significantly greater than
that generated by PMN alone (1.7 X 106 vs. 2.4 X 106; P < 0.05).
The pre-incubation of PMN with iO M TNFa for 30 minutes
resulted in a fourfold increase in respiratory burst activity when
compared with PMN incubated in buffer alone (1.7 x 106 to 7.6 x
106; P < 0.05). When TNFs pre-treated PMN were added to
GBM there was a 20-fold increase in respiratory burst activity
compared to unprimed PMN under the same conditions (2.4 X
106 to 48.1 x 106; P < 0.05).
The co-incubation of TNFn treated PMN, GBM and either
monoclonal antibody to the CD18 moiety of the /32 integrins
(anti-CD 18-1 or 2) resulted in >87% inhibition of the respiratory
burst (Fig. 1). When F(ab')2 fragments of antibody YFC 118.3
(anti-CD 18-2) were added to the reaction mixture the mean
inhibition was >75% (Fig. 1). Conversely the addition of antibod-
ies to the CD11b or to the CD11a subunits of f32 integrins, or an
antibody directed against the FcRIII receptor did not alter the
PMN respiratory burst.
In separate experiments under identical conditions (GBM,
PMN TNFa) there was little or no GBM degradation as
assessed by hydroxyproline release. In particular, priming with
iO M TNFa did not increase hydroxyproline release. GBM
degradation by normal PMN was 1.7% versus 1.9% by TNFa
primed PMN.
Role of FcRJII in GBM-PMN interaction
GBM pre-incubated with purified human IgG to the NC1
domain of type IV collagen induced a respiratory burst from PMN
which was 15-fold greater than that generated by control PMN,
PMN incubated with native GBM, or PMN incubated with
antibody alone (31.1 >< 10' vs. 1,7 X 106, 2.4 x 106 and 1.9 X 106;
P < 0.05). This augmented response was unaffected by pre-
incubation with antibodies to the /32 integrin subunits (CD1 la,b
or CD18). Antibody to the FcRIII receptor, however, reduced
respiratory burst activity by more than 70% (31.1 x 10 to 8.1 X
106; P < 0.05; Fig. 2).
The co-incubation of PMN with GBM-IgG complex resulted in
a significant degradation of GBM as assessed by % hydroxypro-
line release. There was a sixfold increase compared with PMN
stimulated with native GBM (Fig. 3). Pre-treatment of PMN with
monoclonal antibodies to the FcRIII receptor reduced degrada-
tion by >70% (P < 0.05). In contrast antibodies to the subunits of
J32 integrins did not alter GBM degradation.
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Fig. 1. Mean (± SEM) integrated luminol dependent chemiluminescence
(LCL) over 120 minutes incubations of PMN (5 X 10) with GBM (0.5 mg).
PMN were pre-treated with combinations of TNFa and monoclonal
antibodies to different CD antigens and the PMN FcRIII receptor. Results
are the mean of triplicate determinations in experiments with PMN from
6 separate donors.
Combined effects of /32 integrins and FcRJII receptor activation
The interaction of PMN, pre-incubated with iO M TNFa, with
GBM-IgG complex resulted in a respiratory burst which was
30-fold greater than that seen with unprimed PMN and native
GBM (Fig. 4). The response was also greater than the increase
seen with either TNFa primed PMN and native GBM, or
unprimed PMN and GBM-IgG complex. The combined effect of
priming or of anti-GBM antibody was additive to each augmen-
tation process alone. Inhibition with anti-FcRIII antibody reduced
the response to that seen with TNFa priming alone. Similarly,
inhibition with the anti-CD18 antibody reduced the response of
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Fig. 2. Mean (± SEM) LCL generation over 120 mm by PMN incubated with
GBM pre-treated with anti-GBM IgG (GBM-IgG). PMN were also pre-
treated with TNFa and monoclonal antibodies to various CD antigens and
the PMN FcRIII receptor. Results are the mean of triplicate determina-
tions in experiments with PMN from 6 separate donors.
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the PMN to that seen with GBM-IgG complex. As noted previ-
ously antibodies to CD lib or CD ha did not affect GBM-PMN
interaction (Fig. 4).
The pre-incubation of PMN with ifY9 M TNFcc did not,
however, influence the degradation of GBM seen when PMN
were incubated with GBM-IgG. Similarly, the only antibody which
influenced this aspect of interaction was the antibody to the
FcRIII receptor. Co-incubation of anti-FcRIII with PMN and
GBM-IgG reduced the degradation to that seen when PMN were
incubated with native GBM. None of the antibodies to the /32
integrin subunits had any significant effect (Fig. 5).
Discussion
The present study adapts the in vitro model of anti-GBM
disease to study the interaction between PMN, both normal and
primed with TNFcs, and purified intact human GBM and GBM-
anti-GBM IgG complex. Two separate mechanisms were delin-
eated: one which was dependent upon the PMN f32 integrin CD18
subunit, and another which was mediated via PMN FcRIII
receptor interaction with anti-GBM IgG bound to GBM. Priming
Fig. 3. Mean (± SEM) degradation of GBM type [J7 collagen (hydroxyprolmne
release) over six hours by PMN in the presence of GBM, or of GBM
pre-treated with anti-GBM IgG (GBM-IgG). PMN were also pre-treated
with TNFa and monoclonal antibodies to CD antigens and the FcRIH
receptor. Results are the mean of triplicate determinations in experiments
with PMN from 6 separate donors.
of PMN with TNFa resulted in differential augmentation of cell
activation causing increased ROS generation via a CD18 f32
integrin-dependent mechanism without increasing GBM degrada-
tion. In contrast to this, activation of PMN through FcRIII
receptors resulted in both generation of ROS and GBM degra-
dation.
The potential of PMN to damage and degrade insoluble
extracellular matrices in vitro, including GBM, is well described
{20J. In vivo studies have highlighted the fundamental role of
PMN in the pathogenesis of early glomerular injury in glomeru-
lonephritis [1, 3, 21]. In anti-GBM disease tissue localized PMN
are sited in direct contact with GBM either through endothelial
cell fenestrae or after diapedesis through the capillary endothelial
junctions. In this location PMN are able to interact with surface
bound immunoglobulin and complement components as well as
the GBM matrix components themselves via a number of cell
surface receptors 22]. The present model has examined the
possible roles of PMN-derived proteolytic enzymes and ROS in
the degradation of GBM type IV collagen. While normal PMN
were barely activated by GBM alone, in the presence of GBM
with bound anti-GBM IgG they underwent a marked increase in
chemiluminescence in addition to significantly degrading GBM.
Blockade of the PMN FcRIII receptor CD16 markedly reduced
both GBM collagen degradation and PMN chemiluminescence,
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indicating that PMN Fc receptor-mediated interaction was fun-
damental to both facets of PMN activation by this stimulus. This
pattern of PMN stimulation was not seen with either control
GBM or anti-GBM IgG alone, indicating that the binding of
anti-GBM IgG to GBM was an essential prerequisite for the
pro-inflammatory response.
Glomerulonephritis and vasculitis are associated with increased
serum concentrations of pro-inflammatory cytokines including
TNFa [23, 24]. Injection of TNFa induces intraglomerular PMN
accumulation, proteinuria and renal impairment in animals and
exacerbates renal injury in experimental nephritis [10]. Data from
in vitro experiments have shown that TNFa facilitates PMN
interaction with purified individual extracellular matrix compo-
nents to induce PMN adhesion and activation [12, 25, 26]. The
observed increase in chemiluminescence of TNFa primed PMN
above unprimed cells in the GBM free control incubations
confirms that PMN on certain plastics produce ROS in response
to TNFa [12]. However, when incubated in the presence of GBM,
TNFa primed PMN underwent a significantly enhanced chemilu-
minescence response several-fold higher than all control incuba-
tions, indicating a specific interaction between PMN and GBM
itself. Exposure of PMN to nM concentrations of TNFa induces
up-regulation of surface f32 integrin receptors, in particular the
CD11b/CD18 heterodimer, from intracellular storage sites [12, 22,
Fig. 5. Mean degradation (measured by hydroxyproline release) of GBM
type IV collagen (± SEM) by PMN stimulated with GBM-IgG. PMN were
also pre-treated with TNFa and antibodies to CD antigens and the PMN
FcRlII receptor. Results are the mean of triplicate determinations in
experiments with PMN from 6 separate donors.
27]. Interestingly, interactions between CD llb/CD18 and the
complement component iC3b are reduced by peptides containing
the arg-gly-asp (RGD) tripeptide sequence, suggesting that this
family of adhesion molecules, along with the f31, 3 and 6 integrins,
can recognize this ligand motif [28]. Since laminin, one of the
major components of GBM, contains RGD sequences [11], our
observation of TNFa enhanced PMN activation by GBM
prompted us to explore the potential role of PMN /32 integrins in
the process.
Monoclonal antibody blocking experiments in this study
showed that two separate antibodies to the common CD18
component markedly reduced the TNFa augmentation of PMN
activation by GBM. Blockade of two of the a subunits, however,
had no effect. Another group has reported increased adherence of
PMN to purified heterologous matrix components such as lami-
nm, type IV collagen and fibronectin in response to TNFa by a
CD11b/CD18 dependent mechanism [26]. In addition, Nathan et
al showed that PMN adherent to both homologous (fibronectin,
fibrinogen and thrombospondin) and heterologous (laminin) ex-
tracellular matrix proteins released the ROS hydrogen peroxide in
response to TNFa [121. Our observations extend these data to
demonstrate that the intact TNFa primed PMN interaction with
homologous GBM is CD18 dependent.
Although the /32 integrins on PMN are believed to be primarily
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Fig. 4. Mean LCL generation (± sEM) induced in PMN stimulated with
GBM pre-treated with anti-GBM IgG (GBM-IgG). PMN were also pre-
treated with TNFa and antibodies to CD antigens and FcRIII receptors.
Results are the mean of triplicate determinations in experiments with
PMN from 6 separate donors.
Donovan et a!: Role of CD18 in PMN interaction with GBM 703
involved in cell-cell adhesion [27], our data support previous
suggestions that cell-matrix interactions through f32 integrins can
result in potent pro-inflammatory intracellular signal transduction
which is augmented by TNFa [12, 25, 26]. Priming of PMN with
TNFa is thought to achieve this through various mechanisms
including an increase in PMN surface 132 integrin numbers,
clustering of the receptors close to the ligand binding area, or by
the qualitative up-regulation of receptor function [29—31]. Prim-
ing of PMN with TNFa significantly increases the expression of
the CD11b/CD18 heterodimer of the (32 integrins [29], but neither
antibody to the CD11b subunit was effective in ameliorating the
PMN activation. In the present study the clear inhibitory effect of
both anti-CD18 mAb in the absence of inhibition by anti-CD11a
and b mAbs could be due to several factors.
First, the epitope on GBM recognized by the 132 integrins may
not have been the same as the epitope recognized by either of the
anti-CD11 mAb (since antibodies to the same a subunits have
been shown to distinguish different functional epitopes within that
moiety [27]). Identification of the precise binding site could only
be delineated by more extensive mAb studies which would block
all known functional sites within the putative a subunit of the
receptor. Although antibodies to the CD1 ic subunit were not
studied, this receptor is present in small numbers on both resting
and activated PMN [29]. Its role in this system is, therefore, likely
to have been minimal.
Second, in normal PMN the a subunits are phosphorylated,
while the CD18 component is not [29]. Stimulus induced phos-
phorylation of CD18 is a possible mechanism for enhancing
CD11!CD18-mediated PMN activation [32]. It could be argued
that the anti-CD 18 mAbs prevented GBM-induced PMN activa-
tion in this model by binding to CD18 and preventing or amelio-
rating its phosphorylation.
Third, it is possible that binding of the anti-CD 18 mAb may also
have obstructed the ligand binding site elsewhere on the integrin
[12], although the similar reduction in PMN chemiluminescence
seen with intact YFC 118.3 mAb and Fab'2 fragments makes this
unlikely. Finally, since modifications of the CD18 subunit itself,
such as its sulphation, can influence the ligand specificity of the
whole heterodimeric complex [29], the PMN activation by GBM
could have been effectively inhibited by anti-CD18 mAb if they
influenced such changes.
The present study showed that while TNFa primed PMN
underwent a CD 18-dependent respiratory burst, the extent to
which they degraded GBM collagen was unaffected by both TNFa
priming and the addition of specific anti-f32 integrin mAbs.
Indeed, as stated above, the degradative aspect of PMN activation
appeared to be entirely Fc dependent. These data support previ-
ous work which has shown that TNFa facilitates adhesion of PMN
to matrix components with degranulation of specific and tertiary
but not primary granules [25]. Since primary or azurophil granules
contain the major GBM degrading proteolytic enzymes TNFa
would not necessarily augment the mechanism.
In summary, these data show that within the glomerulus in
anti-GBM disease, PMN in contact with GBM-anti-GBM com-
plex may be activated by at least two mechanisms. The first is (32
integrin dependent, inducing PMN ROS generation and which is
markedly enhanced by the pro-inflammatory cytokine TNFa.
These data, and those obtained in a number of animal models in
which pre-treatment of animals with mAb to (32 integrin subunits
has been shown to ameliorate renal injury [331, have highlighted
the potential importance of this mechanism in the propagation of
the inflammatory response by PMN. The second mechanism is Fc
receptor dependent, unaffected by TNFa and induces both ROS
generation and GBM type IV collagen degradation. This homol-
ogous model of human anti-GBM disease provides insight into
some of the mechanisms which may occur at the GBM-PMN
interface during PMN dependent glomerulonephritis. While the
data from these experiments support a role for TNFa GBM in the
activation of PMN, the marked increase in ROS generation did
not directly degrade GBM type IV collagen. Clearly this model is
limited in that it does not reflect fully local in vivo glomerular
structure. In particular, it does not consider the contribution of
the endothelial cells either in a pro- or anti-inflammatory manner.
In addition, within intact glomeruli the ROS generated by the
PMN could directly injure glomerular cells and may alter the
functional properties of GBM components without the concomi-
tant release of soluble peptides of type IV collagen. Thus,
although there were no directly measurable effects attributable to
PMN derived ROS and TNFa in this model, the data do not
allude to other potentially injurious sequelae that could occur in
vivo.
Reprint requests to Kieron L. Donovan, Institute of Nephrology, Royal
Infirmaty, Newport Road, Cardiff CF2 1SZ, Wales, United Kingdom.
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